Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.75 |
| ▸ | HRH1 | P35367 | 1/20 | 0.75 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | FPR1 | P21462 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | RECQL | P46063 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | SLC15A2 | Q16348 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9528755 | 1.00 | CYP2C19 (0.75) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| SCHEMBL9580302 | 1.00 | CYP2C19 (0.75) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| SCHEMBL9325621 | 1.00 | CYP2C19 (0.75) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL11802688 | 0.99 | CYP2C19 (0.74) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| Water SCHEMBL10924164 | 0.99 | CYP2C19 (0.74) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| SCHEMBL11546552 | 0.90 | CYP3A4 (0.71) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| SCHEMBL11590266 | 0.90 | CYP2C19 (0.75) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| SCHEMBL11590270 | 0.90 | CYP2C19 (0.75) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL11708138 | 0.89 | CYP2C19 (0.74) | CYP2C19HRH1SLC22A8POLBCYP3A4 | |
| SCHEMBL11707564 | 0.89 | CYP2C19 (0.74) | CYP2C19HRH1SLC22A8POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534438-B2 | Composition containing piperacillin, pharmaceutical formulation thereof and use thereof | XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210069183-A1 | COMPOSITION CONTAINING PIPERACILLIN, PHARMACEUTICAL FORMULATION THEREOF AND USE THEREOF | XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3094492-B1 | LAMINATED BAG FOR PHARMACEUTICALS | CENTRIENT PHARMACEUTICALS NETHERLANDS B V (NL) | 2019-05-15 | — | — | EP | disclosed |
| EP-3094492-A1 | LAMINATED BAG FOR PHARMACEUTICALS | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2016-11-23 | — | — | EP | disclosed |
| US-20160331638-A1 | LAMINATED BAG FOR PHARMACEUTICALS | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2016-11-17 | — | — | US | disclosed |
| WO-2015107016-A1 | LAMINATED BAG FOR PHARMACEUTICALS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2015-07-23 | — | — | WO | disclosed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| EP-0638649-B1 | New use of alcaligenes faecalis penicillin G acylase | DSM NV (NL) | 1999-11-17 | — | — | EP | disclosed |
| EP-0638649-A2 | New use of alcaligenes faecalis penicillin G acylase | GIST-BROCADES N.V. (NL) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | CYP2C19 2676/4885HRH1 1850/4885SLC22A8 481/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | CYP2C19 2473/4885HRH1 3845/4885SLC22A8 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.